摘要
目的探讨帕利哌酮缓释片治疗首发精神分裂症中的临床效果,并评价其临床用药安全性。方法将46例首发精神分裂症患者随机分为观察组及对照组,每组23例,观察组患者给予帕利哌酮缓释片治疗,对照组患者给予利培酮治疗,用药治疗8周,以阳性和阴性症状量表(PANSS)及个人和社会功能量表(PSP)评价临床疗效,以实验室监测以及不良反应量表(TESS)评价治疗安全性。结果治疗8周末,观察组患者治疗总有效率为95.65%,对照组患者治疗总有效率为86.96%,2组疗效比较差异无统计学意义(P>0.05)。对照组患者治疗2、4、8周末PANSS总分、阳性症状评分、阴性症状评分、一般精神病理评分与治疗前比较均显著降低(P<0.05,P<0.01)。观察组患者治疗1、2、4、8周末PANSS总分、阳性症状评分、一般精神病理评分与治疗前比较均显著降低(P<0.05,P<0.01);2、4、8周末阴性症状评分与治疗前比较均显著降低(P<0.05,P<0.01)。治疗1、2、4、8周末,观察组患者PANSS总分、阳性症状评分、阴性症状评分、一般精神病理评分与对照组比较差异均无统计学意义(P>0.05)。治疗4、8周末2组患者PSP评分均较治疗前显著升高(P<0.05,P<0.01),治疗4、8周末观察组患者PSP评分略高于对照组,但差异无统计学意义(P>0.05)。治疗8周末,2组患者TESS评分比较差异无统计学意义(P>0.05)。在治疗过程中观察组和对照组不良反应的发生例数逐渐增加,主要为头晕、口干、焦虑、便秘、嗜睡、体位性低血压、静坐不能、肌强直和震颤、催乳素升高,均为轻度或中度,经对症治疗或随治疗时间延长,不良反应逐渐减轻或消失,观察组患者锥体外系反应(静坐不能、肌强直和震颤)发生率(21.74%)显著低于对照组(52.17%)(P<0.05)。结论帕利哌酮缓释片治疗首发精神分裂症,起效快,临床治疗效果较好,患者锥体外系等不良反应较少,社会功能改善较明显,安全性�
Objective To explore the efficacy and safety of paliperidone extended-release in the treatment of first-episode schizophrenic patients. Methods Forty-six patients with schizophrenia were randomly divided into observation group and control group,with 23 patients in each group. The patients in observation group were given paliperidone extended-release,and the patients in control group were given risperidone for eight weeks. The positive and negative syndrome scale（ PANSS）,personal and social performance（ PSP） were adopted to measure the efficacy; the treatment emergent symptom scale（ TESS） and laboratory examinations were adopted to measure the safety. Results At the end of eight weeks,the effective rate in observation group and control group was 95. 65% and 86. 96% respectively; there was no statistic difference of the effective rate between the two groups（ P〉0. 05）. Compared with those before treatment,the total scores of PANSS,positive symptom scores,negative symptom scores and the general psychopathology scores in control group decreased at the end of 2,4,8 weeks（ P〈0. 05,P〈0. 01）. Compared with those before treatment,the total scores of PANSS,positive symptom scores and the general psychopathology scores in observation group decreased at the end of 1 week,2,4,8 weeks（ P〈0. 05,P〈0. 01）; Compared with that before treatment,the negative symptom scores in observation group decreased at the end of 2,4,8 weeks（ P〈0. 05,P〈0. 01）. There was no significant difference in total scores of PANSS,positive symptom scores,negative symptom scores and the general psychopathology scores at the end of 1 week and 2,4,8 weeks between the two groups（ P〉0. 05）. Compared with that before treatment,the PSP scores at the end of 4,8 weeks increased significantly in the two groups（ P〈0. 05,P〈0. 01）.At the end of 4,8 weeks,there was no statistic difference of the PSP score between the observation group and the control group（ P〉0. 05）. There was no statistic difference of the TES
出处
《新乡医学院学报》
CAS
2015年第11期1015-1018,共4页
Journal of Xinxiang Medical University
